Invivyd (NASDAQ:IVVD) Shares Up 10.6% – What’s Next?

Invivyd, Inc. (NASDAQ:IVVD)’s share price shot up 10.6% on Friday . The stock traded as high as $2.72 and last traded at $2.7750. 986,174 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 2,360,294 shares. The stock had previously closed at $2.51.

Analysts Set New Price Targets

A number of brokerages recently commented on IVVD. D Boral Capital lowered shares of Invivyd from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. D. Boral Capital reissued a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th. HC Wainwright increased their price objective on Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, BTIG Research assumed coverage on Invivyd in a research report on Monday, December 22nd. They issued a “buy” rating and a $10.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $8.00.

Invivyd Stock Performance

The company has a fifty day moving average price of $2.30 and a two-hundred day moving average price of $1.52. The company has a market cap of $587.47 million, a P/E ratio of -5.36 and a beta of 0.61.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $13.13 million for the quarter, compared to analyst estimates of $12.00 million. Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%. Research analysts anticipate that Invivyd, Inc. will post -1.64 EPS for the current year.

Insider Buying and Selling at Invivyd

In other news, Director Kevin F. Mclaughlin bought 50,000 shares of the stock in a transaction that occurred on Wednesday, November 19th. The shares were acquired at an average cost of $2.50 per share, for a total transaction of $125,000.00. Following the completion of the acquisition, the director owned 50,000 shares in the company, valued at approximately $125,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 25.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IVVD. RA Capital Management L.P. bought a new stake in shares of Invivyd in the 3rd quarter valued at about $18,831,000. ADAR1 Capital Management LLC acquired a new position in Invivyd during the third quarter worth approximately $8,108,000. Vanguard Group Inc. raised its stake in Invivyd by 46.7% in the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock valued at $6,339,000 after buying an additional 1,834,970 shares during the period. 683 Capital Management LLC lifted its position in shares of Invivyd by 2.3% in the second quarter. 683 Capital Management LLC now owns 3,070,000 shares of the company’s stock valued at $2,195,000 after buying an additional 70,000 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Invivyd by 15.8% during the 3rd quarter. Millennium Management LLC now owns 1,446,615 shares of the company’s stock worth $1,591,000 after acquiring an additional 197,522 shares during the period. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.